0001826834-23-000001.txt : 20230620 0001826834-23-000001.hdr.sgml : 20230620 20230620153801 ACCESSION NUMBER: 0001826834-23-000001 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230620 EFFECTIVENESS DATE: 20230620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biopharmaceutical Research Co CENTRAL INDEX KEY: 0001826834 IRS NUMBER: 820650107 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-452292 FILM NUMBER: 231024866 BUSINESS ADDRESS: STREET 1: 11045 COMMERCIAL PARKWAY CITY: CASTROVILLE STATE: CA ZIP: 95012 BUSINESS PHONE: 831-632-0913 MAIL ADDRESS: STREET 1: 11045 COMMERCIAL PARKWAY CITY: CASTROVILLE STATE: CA ZIP: 95012 D/A 1 primary_doc.xml X0708 D/A LIVE 0001826834 Biopharmaceutical Research Co 11045 COMMERCIAL PARKWAY CASTROVILLE CA CALIFORNIA 95012 831-632-0913 DELAWARE Biopharmaceutical Research Company, LLC None Corporation true George Bennett Hodgin 11045 Commercial Parkway Castroville CA CALIFORNIA 95012 Executive Officer Director Charles Schumacher 11045 Commercial Parkway Castroville CA CALIFORNIA 95012 Director Edward Howard Goodwin 11045 Commercial Parkway Castroville CA CALIFORNIA 95012 Director Other Technology Decline to Disclose 06b true 0001826834-22-000003 2022-07-05 false true true Total Offering Amount includes the amount related to the conversion of notes into shares of Series A Preferred Stock. The issuance of such convertible notes was reported in September 2020 as a debt and option right to acquire another security. false 0 North Point Mergers and Acquisitions, Inc. 133300 None None 580 California Street, Suite 2000 San Francisco CA CALIFORNIA 94104 AZ ARIZONA CA CALIFORNIA CT CONNECTICUT GA GEORGIA KS KANSAS LA LOUISIANA MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA PA PENNSYLVANIA TN TENNESSEE TX TEXAS WA WASHINGTON false 23156923 23156923 0 false 36 1191000 true 0 0 false Biopharmaceutical Research Co /s/ George Bennett Hodgin George Bennett Hodgin Chief Executive Officer 2023-06-20